[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-hypertension-oh\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-hypertension-oh":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641250","phase-3-a-comparative-randomized-investigator-blind-active-controlled-parallel-group-multicenter-clinical-endpoint-study-100641250",false,"NCT07661329","A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study","A Comparative Randomized, Investigator-Blind, Active-Controlled, Parallel-Group, Multicenter, Clinical Endpoint Study to Evaluate Efficacy and Safety of Bimatoprost Ophthalmic Solution 0.01% (YSBP) of YS Life Science Co., Ltd. (YSLS) and Lumigan® (Bimatoprost Ophthalmic Solution) 0.01% of AbbVie INC, in the Treatment of Subjects With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH).","Inclusion Criteria:\n\n* Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.\n* Male or females aged ≥18 years.\n* Subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in both eyes\n* Subjects requiring treatment in both the eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.\n* Adequate washout period prior to baseline (Day 0) of any ocular hypotensive medications\n* Baseline (Day 0\u002Fhour 0) IOP ≥22 mm Hg and ≤ 34 mm Hg in both eyes, with difference between the IOP in left and right eyes not being more than 5 mm Hg\n* Subjects' IOP is likely to be controlled with monotherapy.\n* Baseline best corrected visual acuity equivalent to Snellen acuity of 20\u002F100 or better in each eye, using a logarithmic visual acuity chart.\n* Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the study participation) practicing any of the following acceptable methods of contraception:\n\n  1. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication.\n  2. Intrauterine device (IUD) or intrauterine system (IUS)\n  3. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)\n  4. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)\n  5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation\n  6. Total abstinence; partial abstinence is not acceptable\n* No history of addiction to any recreational drug or drug dependence or alcohol addiction\n\nExclusion Criteria:\n\n* Female subjects with positive pregnancy test or lactating or planning a pregnancy.\n* Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation or benzalkonium chloride.\n* Current or history of severe hepatic or renal impairment.\n* Current or history within 3 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts will be allowed provided that the other inclusion\u002Fexclusion criteria are met).\n* Current corneal abnormalities that would prevent accurate IOP readings with tonometer.\n* Functionally significant visual field loss as determined by perimetry.\n* Subjects with corneal grafts.\n* Subject has contraindication to pupil dilation.\n* Use at any time prior to baseline of an intraocular corticosteroid implant.\n* Use of contact lens within 1 week prior to baseline.\n* Use within 21 days prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid.\n* Use within 21 days prior to baseline of a systemic corticosteroid.\n* Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid.\n* Underwent within 3 months prior to baseline any other intraocular surgery (e.g., cataract surgery).\n\nUnderwent any filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty) within 3 months prior to baseline or refractive surgery at any time.\n\n* Subjects with a history of non-responder to bimatoprost monotherapy.\n* Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination.\n* Severe glaucoma with a cup\u002Fdisk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion).\n* Chronic use of any systemic medication that may affect IOP with less than 2 months stable dosing regimen (i.e., sympathomimetic agents, betaadrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)\n* Central Corneal thickness (CCT) \\\u003C480 microns or \\>620 microns for study eye.\n* Known history or presence of any uncontrolled systemic disease\n* History of recurrent ocular seasonal allergies within past 2 years prior to screening.\n* Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements.\n* Participation in any clinical study within 30 days before the first dose of the study drug.\n* Subjects with known cases of active Hepatitis B virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection.\n* Subjects with aphakia or history of herpes simplex keratitis","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.",[26,27],"Primary Open Angle Glaucoma (POAG)","Ocular Hypertension (OH)","RECRUITING","2026-06-16",{"date":31,"type":32},"2026-06-22","ACTUAL",{"date":34,"type":32},"2026-06-02",{"date":36,"type":20},"2027-12-31",{"name":38,"class":39},"YS Life Science Co., Ltd.","INDUSTRY",16,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100623768","observational-trial-of-the-updated-inserter-for-the-travoprost-intracameral-implant-75mcg-100623768","NCT07400926","Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg","Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg","TRIO","Inclusion Criteria:\n\n* Diagnosis of Open-angle glaucoma\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Subject who is breast-feeding or pregnant",{"count":50,"type":20},30,"OBSERVATIONAL","Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)",[54,27],"Open Angle Glaucoma (OAG)",[56,57],"Glaucoma","Ocular Hypertension","2026-02-24",{"date":60,"type":32},"2026-02-27",{"date":62,"type":32},"2025-12-17",{"date":64,"type":20},"2026-07",{"name":66,"class":39},"Glaukos Corporation",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":67},"100580112","transscleral-selective-laser-trabeculoplasty-project-100580112","NCT06833060","Transscleral Selective Laser Trabeculoplasty Project","Exploratory Clinical Study of a Laser-OCT Integrated System With Eye Tracking to Treat Glaucoma and OHT With Transscleral Selective Laser Trabeculoplasty Technology A Pilot Study","TSLT project","Inclusion Criteria:\n\n* Age 18 years or older with OAG or OHT who are clinical candidates for routine SLT.\n* Mild to moderate OAG (defined as a mean deviation on the Humhprey Field Analyzer \\[HFA\\] \\> -12.0 dB), resulting from primary open-angle glaucoma (POAG), or pseudoexfoliative glaucoma\n* OHT with open angles warranting IOP-lowering treatment\n* IOP ≥ 22mmHg or ≤ 35mmHg (after washout of any IOP-lowering medications)\n* Gonioscopically visible scleral spur for 360 degrees without indentation\n* Ability to visualize the peri-limbal sclera for 360 degrees (using a manual elevation of the lid)\n* Willing and able to participate in the 60 days +\u002F-5 days study, to comply with the study procedures and to adhere to the follow-up schedule.\n* Participant capable of giving informed consent\n\nExclusion Criteria:\n\n* Contraindications to conventional SLT (e.g. corneal abnormalities etc.)\n* Angle Closure Glaucoma\n* Congenital or developmental glaucoma\n* Secondary glaucoma included pigmentary glaucoma\n* Inability to conduct a reliable visual field (defined as fixation losses, false positives or false negatives greater than 33%)\n* Presence of any peripheral anterior synechiae (PAS) in the study eye\n* Any of the following visual field findings using the Humphrey visual field analyzer:\n\n  * A HFA MD of worse than -12dB\n  * Greater than or equal to 75% of points depressed below the 5% level and greater than or equal to 50% of points depressed below the 1% level on the PD plot\n  * At least 50% of points (i.e., 2 or more) within the central 5 degrees with a sensitivity ≤0dB on the decibel plot\n  * Points within the central 5 degrees of fixation with a sensitivity \\\u003C15 dB in both hemifields on the decibel plot\n  * A visual field MD of worse than -12dB in the fellow eye\n* Cup: Disc Ratio more than 0.8\n* More than two hypotensive medications required (combination drops are considered 2 medications)\n* Prior incisional or laser glaucoma surgery (including previous SLT) in the study eye\n* Prior corneal refractive surgery\n* Complicated cataract surgery ≤ 6 months prior to enrollment\n* Presence of visually significant cataract in the opinion of the investigator\n* Clinically significant disease in either eye as determined by the Investigator\n* Clinically significant amblyopia in either eye\n* Dense pigmentation or hemorrhage in the peri-limbal conjunctiva or anterior sclera, Pigmented Pinguecula and Pterigium\n* Women who are pregnant or may become pregnant during the course of the study\n* In the opinion of the investigator the participant might require other ocular surgery within the 12-months, unless for further reduction of their IOP.\n* Concurrent treatment with topical, nasal, inhaled or systemic steroids.\n* Uncontrolled systemic disease that could impact the ability of the participant to attend follow up visits as per the discretion of the investigator\n* Participation in another clinical study\n* Protected or vulnerable subjects (including but not limited to people with impaired intellectual functioning or mental illness, prisoners, terminally ill subjects, immunocompromised…)\n* People not able to read and understand the informed consent\n* People not able to read and understand English language",{"count":77,"type":20},15,[79],"NA","The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty.\n\nSelective Laser Trabeculoplasty (SLT) is a type of laser therapy that uses short pulses of low-energy light to lower eye pressure. This treatment uses a lens in contact with the front part of the eye (called cornea) which may lead to complications. Transscleral Selective Laser Trabeculoplasty allows the doctor to perform the laser treatment without the lens coming into contact with the cornea, potentially offering a simpler, quicker and safer approach for both participants and doctors.\n\nParticipants will be required to attend four study visits. The first visit will assess the disease, the second will involve the TSLT laser treatment for the participant's condition (glaucoma or ocular hypertension), and the final two visits, at 1 day and 30 days post-treatment, will evaluate the treatment's efficacy and the procedure's safety.",[82,27],"Glaucoma,Open-Angle","2025-06-20",{"date":85,"type":32},"2025-06-26",{"date":87,"type":32},"2025-06-19",{"date":89,"type":20},"2025-11-01",{"name":91,"class":39},"Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)"]